An Open-label, Two-Part, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Hepatic Impairment

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Aug 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs BMS-986263 (Primary)
Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis; Liver cirrhosis
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

26 Jun 2022 Part 2 results were presented at The International Liver Congress 2022.
15 Nov 2021 Results (n=24) presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
29 Oct 2021 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com